Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC

NCT01795794 | Unknown Phase 4

• 1 other identifier: sor034612ctil
• Study Type: interventional
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

Congenital Dyserythropoietic Anemia Type I (CDAI) is a recessive autosomal disease caused by ineffective erythropoiesis that causes Anemia \& accumulation of iron due to increased absorption of iron in the intestine. The iron is being accumulated in the body \& causes damage of the liver, heart \& endocrine glands. The standard follow up of iron levels is done by ferritin blood test \& although the test is not accurate it is the most available. Medical treatment to removal of iron excess from the body is given in ferritin levels of 500-1000. 3 drugs are approved in the market:

• Deferoxamine, given subcutaneous during the night, 5-7 nights/week and therefore is less used today.
• Deferiprone-given 3 times a day, is a weaker chelator, although it seems like it is good to give it in combination with one of the 2 other drugs because it removes the iron from the heart's cells better. A rare but severe adverse effect is Agranulocytosis. This drug is usually not given in childbirths.
• The 3rd drug which is mostly in use today is Deferasirox, given once daily, but has also adverse effects, among them- damage of liver \& kidney function, damage to the digestive system, hearing and seeing. Iron is being absorbed in acidic area, \& thus drugs which decrease the acidity like hydrogen pump's inhibitors, can inhibit the absorption of iron, and indeed there are reports that these drugs decrease the absorption of iron and were used as treatment to hemochromatosis as well. Those hydrogen pump's inhibitors have also adverse effects. The rarest but most severe is intestine infection by Clostridium. In children, reports of adverse effects are minimal- mostly headaches \& abdominal pains and nosocomial infections. In adults, there are reports of fractures, magnesium deficiency \& vitamin B12 deficiency. All in all, the adverse effects are rare \& uncommon.

Conditions

CDA Type I

Outcome Measures

Primary Outcomes (1)

• evaluate number of adverse effects per patient treated with LOSEC + levels of iron, ferritin,complete blood count and chemistry panel.

  1 year

Study Arms (1)

LOSEC

EXPERIMENTAL

LOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the "control" group of herself.

Drug: omeprazole

Interventions

omeprazole DRUG

Also known as: losec

LOSEC

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• patients with CDAI
• over 30 kg
• can swallow tablets
• ferritin levels higher than the normal range but still don't require treatment.

You may not qualify if:

• N.A

Sponsors & Collaborators

• Soroka University Medical Center: lead

MeSH Terms

Interventions

Omeprazole

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 11, 2013
• First Posted: February 21, 2013
• Study Start: April 1, 2013
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2013
• Last Updated: February 27, 2013

Record last verified: 2013-02